ASSOCIATION OF SERUM INSULIN GROWTH FACTOR I WITH DEMENTIA IN PARKINSON ’S DISEASE
Main Article Content
Keywords
IGF-1, Parkinson’s disease, neurodegeneration, dementia
Abstract
Background: Parkinson’s disease or PD is a motor plus cognitive disorder resulting from dopamine’s loss in the substantia nigra in the brain. About 1.5–2% of people older than the age of 60 suffer from PD, with dementia developing as a terminal state in response to neuronal death and activation of glial cells in the brain.
Objectives: To assess and compare the serum levels of insulin like growth factor IGF1 in patients of Parkinson's Disease with Dementia and Without Dementia, and Normal Control Population
Study design: A cross-sectional study.
Place and duration of study. Rai Medical College Sargodha over the period from September 1, 2021, to August 31, 2022.
Methods: The present comparative study is cross-sectional and performed at Rai Medical College Sargodha over the period from September 1, 2021 to August 31, 2022. Ninety subjects were divided into three groups: PD patients with dementia, PD patients without dementia, and normal healthy elderly people. The levels of IGF-1 in the serum were determined by enzyme-linked immunosorbent assay (ELISA) and compared for statistical significance.
Results: Slightly more than half of participants was male (54.3%); and the mean age of patients was 68.4 years (SD ± 8.3). Of the measured hormones, circulating serum IGF-1 levels were found to be significantly higher in the PD groups than the controls (A: p < 0.001). Median IGF-1 levels recorded were 3.6 ng/dL (range: 1. By comparing these values, PD subjects with dementia = 1.07 ng/mL (LOQ: 44; HI: 25.96), PD without dementia = 0.34 ng/mL (LOQ: 0.25; HI: 0.49) and healthy controls: = 0.18 ng/mL (LOQ: 0.07; HI: 0.35). On this basis, the role of IGF-1 in the progression of PD, especially in dementia cases, can be assumed.
Conclusion: Several differences were obtained in total IGF-1 levels in the serum of PD patients, and particularly in patients with dementia suggesting the value of this parameter as the biomarker for the PD progression and dementia in particular.
References
2. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. doi:10.1016/S0140-6736(14)61393-3
3. Aslam M, Shehab MA, Abd El-Aty AM. Parkinson's disease in Pakistan: a review of epidemiology and management. Neurol Sci. 2020;41(4):1013-1020. doi:10.1007/s10072-019-04177-1
4. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;397(10291):2284-2303. doi:10.1016/S0140-6736(21)00218-X
5. Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217-231. doi:10.1038/nrneurol.2017.27
6. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837-844. doi:10.1002/mds.21956
7. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683. doi:10.1001/jama.2014.3654
8. Hely MA, Morris JG, Traficante R, et al. The Sydney Multicenter Study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry. 1999;67(3):300-307. doi:10.1136/jnnp.67.3.300
9. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord. 2012;27(1):8-30. doi:10.1002/mds.23795
10. Barbeau A. Environmental toxins and Parkinson's disease: the Quebec experience. Can J Neurol Sci. 1984;11(1 Suppl):174-179. doi:10.1017/S0317167100045720
11. Torres EM, Lane EL, Dunnett SB. The role of insulin-like growth factor I in the central nervous system. Brain Res Rev. 2008;58(2):315-334. doi: 10.1016/j.brainresrev.2008.04.002
12. Chu Y, Morfini GA, Langhamer LB, et al. Alpha-synuclein induces alterations in microtubule dynamics, resulting in transport loss and degeneration in the central nervous system. Acta Neuropathol. 2012;124(4):487-499. doi:10.1007/s00401-012-1016-y
13. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord. 2011;26(6):1049-1055. doi:10.1002/mds.23732
14. Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des. 2005;11(8):999-1016. doi:10.2174/1381612053381620
15. Doi H, Kato S, Kikuchi H, et al. Serum insulin-like growth factor-1 in Parkinson's disease and multiple system atrophy. Mov Disord. 2011;26(4):758-759. doi:10.1002/mds.23525
16. Okamoto N, Morimoto S, Ueno M, et al. Serum insulin-like growth factor-1 levels and activities of daily living in patients with Parkinson's disease. J Clin Neurosci. 2011;18(7):971-973. doi: 10.1016/j.jocn.2010.11.021
17. Xiao Q, Chen S, Le W. Insulin-like growth factor-1 and Parkinson's disease: a promising therapeutic target? Front Biosci (Schol Ed). 2010; 2:388-397. doi:10.2741/s74
18. Athauda D, Foltynie T. Insulin resistance and Parkinson's disease: a new target for disease modification? Prog Neurobiol. 2016;145-146:98-120. doi: 10.1016/j.pneurobio.2016.10.001
19. Buhusi M, Etheredge C, Granholm AC. Insulin-like growth factor I improves hippocampal cholinergic function in an animal model of Down syndrome. Neurobiol Dis. 2004;15(2):365-377. doi: 10.1016/j.nbd.2003.11.010
20. Carro E, Torres-Aleman I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol. 2004;490(1-3):127-133. doi: 10.1016/j.ejphar.2004.02.049
21. Fernandez AM, Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci. 2012;13(4):225-239. doi:10.1038/nrn3209
22. Aberg MA, Aberg ND, Hedbacker H, Oscarsson J, Eriksson PS. Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J Neurosci. 2000;20(8):2896-2903. doi:10.1523/JNEUROSCI.20-08-02896.2000
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Ameena Nasir
Associate Professor of Physiology, King Edward Medical University, Lahore, Pakistan
Qanita Mahmud
Assistant Professor of Physiology, Fatima Jinnah Medical University, Lahore, Pakistan
Muhammad Imran Aftab
Associate Professor of Physiology, Watim Medical College, Rawat, Pakistan
Jaleel Kamran
Associate Professor & Head of Physiology, Watim Dental College, Rawat, Pakistan
Sobia Parveen
Demonstrator, Department of Biochemistry, Rai Medical College, Sargodha, Pakistan